Antibody-Drug Conjugates: Key Challenges in Safety Assessnnent

摘要

The number and types of targeted cancer therapies under development for the treatment of human disease have greatly expanded over the last decade. Targeted therapies, like antibody-drug conjugates, hold particular promise for oncology patients as theyare purposefully designed to minimize systemic toxicity while delivering a highly potent, cytotoxic payload to a target tumor cell population (1, 2). Antibody drug conjugates (ADCs), or immunoconjugates, are hybrid molecules usually comprised of monoclonal antibodies conjugated with potent cytotoxins, but also can consist of other molecules, such as antibody fragments or radioisotopes (Fig. 1).